Do you include pembrolizumab for metastatic/recurrent cervical cancer per KEYNOTE-826 regardless of PDL1 status?

The NCCN guidelines only list Platinum + Taxol + Pembrolizumab +/- Bevacizumab for PDL1-positive tumors.

Community PollStarted

Do you include pembrolizumab in your systemic therapy regimen for metastatic cervical cancer +/- Bevacizumab?

38 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer

Mednet MemberInvited Expert

Gynecologic Oncology · Vanderbilt University School of Medicine

Answered on

PD-L1 expression is the biomarker currently approved for assessing potential responsiveness to immune checkpoint inhibitor (ICI) therapy in cervical and other malignancies. The search for better biomarkers is ongoing. With that caveat, KEYNOTE-826 was a randomized trial of chemotherapy +/- bevacizum...

Join for free or sign in to see the full answer